CBLL

CeriBell, Inc.

• Benzinga·1d ago

  CeriBell Highlights Publication Of New Research Paper, 'Point-Of-Care EEG Artificial Intelligence Measure Of Seizure Burden Associates With Clinical Outcome At Discharge'

• TipRanks·06/02 21:04

  Ceribell Announces Director Elections at 2026 Annual Meeting

• PUBT·06/02 20:19

  Ceribell holds annual shareholder meeting, elects Class II directors

• TipRanks·05/27 02:09

  Ceribell Leadership Unloads Shares in a Wave of Insider Stock Moves

• PUBT·05/26 20:20

  Ceribell Senior VP Finance David Foehr disposes of 1,849 common shares for $33,005.60

• PUBT·05/20 20:06

  Ceribell CEO Jane Chao presents at William Blair Growth Stock Conference

• TipRanks·05/17 13:25

  Bank of America Securities Remains a Buy on Ceribell, Inc. (CBLL)

• TipRanks·05/13 09:16

  Ladenburg Thalmann & Co. Remains a Buy on Ceribell, Inc. (CBLL)

• TipRanks·05/13 06:00

  Middle East Tensions Threaten Ceribell’s Supply Chain, Shipping Routes, and Margins

• Simply Wall St·05/12 23:22

  CeriBell (CBLL) Q1 Loss Widens Challenging Bullish Growth Narratives

• Dow Jones·05/12 19:31

  CeriBell Is Maintained at Buy by Canaccord Genuity

• Dow Jones·05/12 19:31

  CeriBell Price Target Cut to $25.00/Share From $28.00 by Canaccord Genuity

• Benzinga·05/12 19:22

  Canaccord Genuity Maintains Buy on CeriBell, Lowers Price Target to $25

• Seeking Alpha·05/12 13:12

  Ceribell anticipates $112M-$116M 2026 revenue while targeting delirium NTAP of up to $2,171 per patient

• TipRanks·05/12 11:28

  Ceribell price target lowered to $25 from $28 at Canaccord